|
US2021122802A1
|
|
Modified TCR And Uses Thereof
|
|
US2021077528A1
|
|
Modified Cell with Enhanced Functionality and Cellular Therapy thereof
|
|
US2021100841A1
|
|
Presenting cell and use thereof in cell therapy
|
|
US2021060069A1
|
|
Coupled redirected cells and uses thereof
|
|
US2021024890A1
|
|
Modulating t cell function and response
|
|
US2020347367A1
|
|
Activation of APC in Immunotherapy
|
|
US2020339683A1
|
|
Reducing Immune Inhibition Induced by SIGLEC-15
|
|
US2020299354A1
|
|
Inducible Dominant Negative PD-1 and uses in Adoptive Cell Therapy
|
|
WO2020146743A1
|
|
Modified cell expansion and uses thereof
|
|
WO2020106843A1
|
|
Modified cell expressing therapeutic agent and uses thereof
|
|
AU2019327490A1
|
|
Chimeric antigen receptor cells for treating solid tumor
|
